Nephros Inc (NEPH)vsWest Pharmaceutical Services Inc (WST)
NEPH
Nephros Inc
$3.42
-4.74%
HEALTHCARE · Cap: $36.80M
WST
West Pharmaceutical Services Inc
$314.50
-0.89%
HEALTHCARE · Cap: $23.23B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 16743% more annual revenue ($3.22B vs $19.12M). WST leads profitability with a 16.9% profit margin vs 4.1%. WST trades at a lower P/E of 44.1x. WST earns a higher WallStSmart Score of 65/100 (C+).
NEPH
Avoid32
out of 100
Grade: F
WST
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.9%
Fair Value
$4.34
Current Price
$3.42
$0.92 discount
Margin of Safety
-56.0%
Fair Value
$157.79
Current Price
$314.50
$156.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 56.1% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 21.7%
Revenue surging 21.0% year-over-year
Areas to Watch
Smaller company, higher risk/reward
ROE of 7.3% — below average capital efficiency
4.1% margin — thin
Operating margin of 1.9%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NEPH
The strongest argument for NEPH centers on Debt/Equity.
Bull Case : WST
The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.
Bear Case : NEPH
The primary concerns for NEPH are Market Cap, Return on Equity, Profit Margin. A P/E of 48.4x leaves little room for execution misses. Thin 4.1% margins leave little buffer for downturns.
Bear Case : WST
The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.
Key Dynamics to Monitor
NEPH profiles as a value stock while WST is a growth play — different risk/reward profiles.
NEPH carries more volatility with a beta of 1.50 — expect wider price swings.
WST is growing revenue faster at 21.0% — sustainability is the question.
WST generates stronger free cash flow (47M), providing more financial flexibility.
Bottom Line
WST scores higher overall (65/100 vs 32/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?